Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hNPC01 in Chronic Ischemic Stroke
NCT06299033Phase 1Recruiting
- Sponsor
- Hopstem Biotechnology
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hNPC01 in ischemic stroke, sponsored by Hopstem Biotechnology. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 6 months. Started Nov 2023; status: recruiting.
02
Drugs
hNPC01
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06299033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06299033.